Recently, Ribaldone et al. reported data for a mixed cohort of 17 IBD patients managed in a joint gastro-enterologic-dermatologic clinic and treated with subcutaneous IL-23 inhibitors (9 RZB, 8 GUS) at the dosage approved for psoriasis [67]. Here, IL23A is linked to inflammatory bowel disease.